This post is part of Japan: A Special Report for Investors.

"Japan's tsunami has struck worldwide," says Richard Moroney, the editor of Dow Theory Forecasts, which has maintained a model portfolio of blue chip stocks for over 50 years.

Here, he reviews a number of the top buy recommendations in the newsletter's portfolios to determine the potential risk posed by the recent tragic developments in Japan.

Stocks cited as "Focus List Buys" are are those issues that the service expect to significantly outperform the market over the next 12 months.

Analyst Upgrades

• FBR Capital upgraded Franklin Resources (BEN) to outperform from market perform and raised its target price for shares to $127 from $105 to reflect its belief the company is well positioned in the current environment.
• UBS upgraded Nuance (NUAN) to buy from neutral and has an $18 price target on the stock. The firm upgraded shares based on valuation and believes the company could be an acquisition target.
• Morgan Stanley upgraded DryShips (DRYS) to equal weight from underweight and has a $5.50 target on the stock. The firm cites the firmer ultra-deepwater drilling market for the upgrade.
• Becton Dickinson (BDX) was upgraded to neutral from sell at Goldman.
• Edwards Lifesciences (EW) was upgraded to market perform at Rodman & Renshaw.
• Arkansas Best (ABFS) was upgraded to neutral from underperform at BofA/Merrill.

Analyst Upgrades

• Jefferies upgraded Computer Sciences (CSC) to buy from hold and raised its target to $53 from $47. The analyst said Computer Sciences' valuation has created one of the best LBO opportunities in several years and could provide a five year IRR of 25+%.
• Keefe Bruyette upgraded Comerica (CMA) to outperform from market perform, citing strength of the company's capital. The firm raised its target for shares to $44 from $43.
• RBC Capital upgraded Nokia (NOK) to outperform from sector perform and raised its price target to $14 from $12. The firm upgraded shares based on valuation, reduced execution risk on software development, and potential catalysts from new devices based on Symbian^3. RBS upgraded Nokia to buy from hold after the company named Stephen Elop as CEO.
• Allstate (ALL) was upgraded to buy from hold at Citigroup.
• Coca-Cola Enterprises (CCE) was upgraded to buy from neutral at BofA/Merrill.
• Moody's (MCO) was upgraded to overweight from neutral at Piper Jaffray.

Analyst Upgrades

• Auriga upgraded Allscripts (MDRX) to buy from hold to reflect valuation and potential synergies from the company's pending merger with Eclipsys (ECLP). The firm upped its target price for shares to $20 from $19.
• SunTrust upgraded Newell Rubbermaid (NWL) to buy from neutral based on completion of its turnaround plan, stabilizing end markets and favorable comparisons. The firm has a $25 price target on the stock.
• Morgan Joseph upgraded C.R. Bard (BCR) to buy from hold based on valuation and upside to estimates from the share buyback program. The firm has a $97 price target on the stock.
• Shire (SHPGY) was upgraded to buy from hold at Lazard Capital.
• Onyx Pharma (ONXX) was upgraded to outperform from market perform at BMO Capital.
• AvalonBay (AVB) was upgraded to neutral from sell at UBS.

Analyst Upgrades

• Goldman upgraded Walmart (WMT) to buy from neutral, citing compelling valuation, margin expansion and expense control. The firm has a $60 target on the stock.
• FBR Capital upgraded Urban Outfitters (URBN) to outperform from market perform on valuation and its belief that sustainable positive comp trends will return in 2010. The firm maintains a $35 price target on shares.
• JPMorgan upgraded Manpower (MAN) to overweight from neutral. The firm cites valuation and improving temp fundamentals in the U.S. and France for the upgrade and has a $70 price target on the stock.
• Arena Resources (ARD) was upgraded to buy from neutral at SunTrust.
• C.R. Bard (BCR) was upgraded to neutral from underweight at Piper Jaffray.
• Cardinal Health (CAH) was upgraded to overweight from market weight at Thomas Weisel.

Analyst Upgrades

• Deutsche Bank upgraded Research in Motion (RIMM) to hold from sell to reflect the company's Q3 results and guidance. The firm raised its target price on shares to $75 from $60.
• Keefe Bruyette upgraded Northern Trust (NTRS) and State Street (STT) to outperform from market perform to reflect valuation and favorable longer-term secular trends. The firm keeps a $58 price target on Northern Trust and a $51 target on State Street.
• UBS upgraded Universal Health (UHS) to buy from neutral and raised its target to $38 from $31. The firm said hospital checks indicate bad debt has not increased vs. Q3 and that Universal Health should report an in-line to better-than-expected Q4.
• Take-Two Interactive (TTWO) was upgraded to hold from sell at Kaufman Bros.
• Whiting Petroleum (WLL) was raised to outperform from market perform at Wells Fargo.
• BP Plc (BP) was upgraded at Goldman to buy from neutral.

Analyst upgrades:

• Oppenheimer upgraded Viacom (NYSE: VIA, VIA.B) to Outperform from Perform following the better-than-expected Q3 results to reflect an improving outlook for all the company's segments. The firm raised its target on shares to $36.
• Deutsche Bank upgraded C.R. Bard (NYSE: BCR) to Buy from Hold on expectations the company's underlying growth trends will improve. The firm raised its target on shares to $88 from $78.
• Wells Fargo upgraded Cognizant (NASDAQ: CTSH) to Outperform from Market Perform. The firm upgraded the stock after Cognizant reported better-than-expected Q3 results.
• Plug Power (NASDAQ: PLUG) was upgraded to Sector Perform from Underperform at RBC Capital.
• Digital River (NASDAQ: DRIV) was upgraded to Buy from Hold at Collins Stewart and to Overweight from Neutral at Piper Jaffray.
• Steris (NYSE: STE) was upgraded to Overweight from Equal Weight at Stephens.

Analyst upgrades:

• Banc of America/Merrill upgraded Gymboree (NASDAQ:GYMB) to Buy from Underperform and raised their target to $33 from $15 following the company's Q1 comparable store sales guidance.
  
• Oppenheimer upgraded Lam Research (NASDAQ:LRCX) to Outperform from Perform after channel checks indicated the company's shipments are gaining momentum. The firm raised their price target on the stock to $35 from $20.
  
• Owens & Minor (NYSE:OMI) was raised to Outperform from Neutral at Credit Suisse. The firm upgraded shares but lowered their target to $45 from $46 citing underappreciated earnings growth and valuation.
• Albermarle (NYSE:ALB) was upgraded to Conviction Buy from Neutral at Goldman.
  
• Protective Life (NYSE:PL) was upgraded to Neutral from Sell at UBS.
  
• Maxim (NASDAQ:MXIM) was lifted to Buy from Hold at Canaccord.

MOST NOTEWORTHY: Anchor Bancorp, TomoTherapy and Skillsoft Corp were today's noteworthy initiations:

• Keefe Bruyette initiated Anchor Bancorp (NASDAQ: ABCW) with a Market Perform rating and $18 target, as they prefer to wait for credit and capital concerns to subside.
  
• Jefferies believes TomoTherapy (NASDAQ: TOMO) should trade higher based on the company's strong new order growth and would be buyers at current levels. The firm started shares with a Buy rating and $17 target.
  
• Skillsoft (NASDAQ: SKIL) was assumed with an Outperform rating at William Blair, as they believe the NETg acquisition will drive significant operating margin improvement in the coming years.

OTHER INITIATIONS:

• Lehman reinstated MarkWest Energy (NYSE: MWE) with an Overweight rating.
  
• Friedman Billings initiated C.R. Bard (NYSE: BCR) with a Market Perform rating and $102 target.
  
• Wachovia initiated Cooper Industries (NYSE: CBE) and Thomas & Betts (NYSE: TNB) with Market Perform ratings.

On last night's "MAD MONEY" on CNBC, Jim Cramer wanted to show defensive stocks in the medical industrial field. He has seen enough earnings from big companies and he is fed up with the Fed sitting around while the U.S. economy is slowing to a halt. He wants an "Ultimate Defensive Portfolio" of three stocks that are defensive but whose businesses are still growing. He even wanted to take out the companies that are only growing because of foreign business.

1) Bard (C.R.) (NYSE: BCR) is one stock he's been behind since 2005, and he is still behind it. Besides thinking it can still be bought, there is more to like on it, especially its catheter business, but its biopsy technology and the angioplasty operations as well.

2) Becton, Dickinson (NYSE: BDX) is a safe traditional medical device and diagnostics company. BDX has been up 31% since Cramer first recommended it, and he thinks it will go higher. More on BDX here.

3) Baxter International Inc. (NYSE: BAX) was Cramer's #3 spot as the best of breed, but he only wants to buy it now if it sells off. You can read what else he noted on it.

Back in February I came up with a list of 20 Defensive Stocks for a Crummy Market. After those 20 stocks, I even came up with a list of 15 Second Line Defensive Stocks. Many of my names were different than Cramer's names at the time. Some of my picks were medical and some were not, and most were chosen at a time that fear and panic were starting to come front and center. These picks that Cramer came up with are all different in that they may grow, and not only because of the weak dollar.

Jon Ogg is a partner at 24.7 Wall St.; he does not own securities in the companies he covers.